Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
Initial Phase 3 results may be available as early as the end of 2020; complete results are anticipated in January 2021.
-
ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1
ViiV Healthcare present their three-year results from the phase III GEMINI 1 & 2 studies at the HIV Glasgow 2020 congress
-
ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices
ViiV Healthcare work with clinical staff at 18 diverse practice sites across different healthcare systems in France, Spain, Belgium, Germany
-
FDA approves Nucala as the first and only biologic treatment for Hypereosinophilic Syndrome (HES)
Third US indication for Nucala demonstrates GSK’s commitment to finding new ways to help patients with eosinophil-driven diseases
-
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
Agreements relate to vaccine candidate using Sanofi’s recombinant protein-based technology and GSK’s pandemic adjuvant.
-
FDA approves Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US
New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm
-
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
Over 400 participants being enrolled in Phase 1/2 study.
-
Vir Biotechnology and GSK start phase 2/3 study of COVID-19 antibody treatment
Phase 2/3 study will investigate the safety and efficacy of antibody treatment in preventing hospitalisation due to COVID-19.
-
GSK presents promising phase 2a data for chronic hepatitis B treatment
Chronic hepatitis B is a major global health problem that occurs when the body’s immune system is unable to fight off the virus.
-
Low adult immunization rates decline further due to pandemic
Prior to pandemic, less than half of adults received the vaccines recommended for their age group.
-
GSK announces first participant vaccinated in phase 3 clinical trials of its 5-in-1, meningitis ABCWY vaccine candidate
The trial will evaluate safety, tolerability and immunogenicity of GSK’s MenABCWY vaccine candidate compared to Bexsero and Menveo.
-
GSK announces $10M program to advance Black people, Latinx people, women in STEM
$10 million over 10 years to help Black, Latinx and female Philadelphia students overcome obstacles to their pursuit of careers in STEM
-
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma
-
GSK launches national public awareness campaign to reverse steep decline in already low immunization rates for adults
GSK launches national public awareness campaign to reverse steep decline in already low immunization rates for adults
-
Sanofi and GSK selected for Operation Warp Speed to supply United States Government with 100 million doses of COVID-19 vaccine
Promising COVID-19 vaccine candidate, developed by Sanofi in partnership with GSK, selected by U.S. government’s Operation Warp Speed.
-
GSK to share evidence supporting a personalised approach to asthma treatment at ATS 2020 Virtual
GSK to share evidence supporting a personalised approach to asthma treatment at ATS 2020 Virtual
-
GSK delivers Q2 sales of £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*)
GSK delivers Q2 sales of £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*)
-
Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
Agreement relates to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system.
-
GSK begins shipping record number of its influenza vaccine doses for 2020-21 season for US market
GSK produces largest supply ever as CDC urges adults and high-risk individuals to be immunized against influenza during COVID-19 pandemic
-
GSK and CureVac announce strategic mRNA technology collaboration
GSK and CureVac announce strategic mRNA technology collaboration
